Tous les communiqués de presse

all press releases
  • Legend
  • corporate
  • finance
  • sciences
  • Cellectis S.A. to Explore Possible Initial Public Offering of Calyxt, Inc.

    April 12, 2017 – Cellectis (Alternext: ALCLS; Nasdaq: CLLS) today announces that it is exploring the possibility of an initial public offering (IPO) of a minority interest in its plant sciences business, Calyxt, Inc. No decisions have been taken at this point on the structure or timing of any IPO, and no assurance can be given that an IPO will be pursued.

    read more download
  • Monthly information on share capital and company voting rights

    read more
  • Corporate Presentation March 2017

    read more
  • Cellectis to Present at the 2017 Annual Conference of the American Association for Cancer Research

    New York, N.Y. – March 29, 2017 – Cellectis (Alternext: ALCLS; Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR T-cells (UCART), today announced that data on its gene-edited allogeneic CAR T-cells will be presented at the American Association for Cancer Research (AACR) Annual Meeting. This includes both wholly-controlled Cellectis programs and Pfizer/Cellectis collaboration programs. The meeting will be held from April 1st to April 5th, 2017 in Washington, D.C., USA.

    read more download
  • FORM 20-F

    read more download